HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Modafinil improves symptoms of attention-deficit/hyperactivity disorder across subtypes in children and adolescents.

AbstractOBJECTIVE:
This secondary analysis evaluated the efficacy of modafinil in children and adolescents by subtype of attention-deficit/hyperactivity disorder (ADHD) using pooled data from 3 double-blind, placebo-controlled studies.
STUDY DESIGN:
The patients were boys and girls age 6 to 17 years. ADHD subtype diagnoses (ie, inattentive, hyperactive-impulsive, combined) were based on criteria published in the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV). Patients received modafinil (170 to 425 mg) or placebo once daily for 7 to 9 weeks. Efficacy assessment used the Attention-Deficit/Hyperactivity Disorder Rating Scale-IV (ADHD-RS-IV) School and Home Versions, Clinical Global Impression of Improvement scale (CGI-I), and Conners' Parent Rating Scale-Revised: Short Form (CPRS-R:S).
RESULTS:
A total of 638 patients received modafinil (n = 423) or placebo (n = 215). The inattentive, hyperactive-impulsive, and combined subtypes included 187 (30%), 27 (4%), and 403 (65%) patients, respectively. Modafinil (vs placebo) significantly improved mean total scores for the ADHD-RS-IV School and Home Versions for the inattentive (change from baseline: School, modafinil, -15.7, placebo, -7.1; Home, modafinil, -13.8, placebo, -5.9) and combined subtypes (School, -16.5 vs -8.8; Home, -15.7 vs -7.6). Modafinil was associated with greater improvements on the CGI-I and improved CPRS-R:S subscale scores in inattentive and combined subtypes.
CONCLUSIONS:
Modafinil improved ADHD symptoms and behaviors in patients with the inattentive and combined subtypes as determined by teachers, investigators, and parents.
AuthorsJoseph Biederman, Steven R Pliszka
JournalThe Journal of pediatrics (J Pediatr) Vol. 152 Issue 3 Pg. 394-9 (Mar 2008) ISSN: 1097-6833 [Electronic] United States
PMID18280848 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Benzhydryl Compounds
  • Central Nervous System Stimulants
  • modafinil
Topics
  • Adolescent
  • Age Factors
  • Attention Deficit Disorder with Hyperactivity (diagnosis, drug therapy)
  • Benzhydryl Compounds (administration & dosage)
  • Central Nervous System Stimulants (administration & dosage)
  • Child
  • Confidence Intervals
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Drug Administration Schedule
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Neuropsychological Tests
  • Probability
  • Randomized Controlled Trials as Topic
  • Reference Values
  • Risk Assessment
  • Severity of Illness Index
  • Sex Factors
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: